New technique could be used to choose best therapies for patients and measure their effectiveness
Evaluating the effectiveness of therapies for neurodegenerative diseases is often difficult because each patient’s progression is different. A new study shows artificial intelligence (AI) analysis of blood samples can predict and explain disease progression, which could one day help doctors choose more appropriate and effective treatments for patients.
Scientists at The Neuro (Montreal Neurological Institute-Hospital) of McGill University and the Ludmer Centre for Neuroinformatics and Mental Health used an AI algorithm to analyze the blood and post-mortem brain samples of 1969 patients with Alzheimer’s and Huntington’s disease. Their goal was to find molecular patterns specific to these diseases.
The algorithm was able to detect how these patients’ genes expressed themselves in unique ways over decades. This offers the first long-term view of molecular changes underlying neurodegeneration, an important accomplishment because neurodegenerative diseases develop over years.
Previous studies of neurodegeneration often used static or “snapshot” data, and are therefore limited in how much they can reveal about the typically slow progression of disease. This study aimed to uncover the chronological information contained in large-scale data by covering decades of disease progression, revealing how changes in gene expression over that time are related to changes in the patient’s condition.
Furthermore, the blood test detected 85 to 90 per cent of the top predictive molecular pathways that the test of post-mortem brain data did, showing a striking similarity between molecular alterations in both the brain and peripheral body.
“This test could one day be used by doctors to evaluate patients and prescribe therapies tailored to their needs,” says Yasser Iturria-Medina, the study’s first author. “It could also be used in clinical trials to categorize patients and better determine how experimental drugs impact their predicted disease progression.”
Iturria-Medina says his next steps will be testing these models in other diseases such as Parkinson’s disease and amyotrophic lateral sclerosis.
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
AI-analyzed blood test
- McGill Universityon February 16, 2020 at 4:00 pm
McGill University was established in 1821 in Montreal, Quebec, Canada. McGill University has over 34,000 undergraduate, graduate and professional degree students. The university is rated high for ...
- AI-analyzed blood test can predict the progression of neurodegenerative diseaseon January 30, 2020 at 5:08 pm
McGill University. "AI-analyzed blood test can predict the progression of neurodegenerative disease: New technique could be used to choose best therapies for patients and measure their effectiveness." ...
- Can AI predict heart failure?on January 30, 2020 at 4:00 pm
The AI analyzed scans of 256 patients' hearts, measuring 30,000 different points in the organ's structure during each heartbeat and analyzed blood test results. The MRC was investigating patients with ...
- New Injection Technique May Boost Spinal Cord Injury Repair Effortson January 30, 2020 at 1:10 pm
The researchers plan to test the cell delivery system in larger preclinical animal models of spinal traumatic injury that more closely mimic human anatomy and size. “The goal is to define the optimal ...
- AI-analyzed blood test can predict the progression of neurodegenerative diseaseon January 30, 2020 at 1:06 pm
Furthermore, the blood test detected 85 to 90 per cent of the top predictive molecular pathways that the test of post-mortem brain data did, showing a striking similarity between molecular alterations ...
Go deeper with Google Headlines on:
AI-analyzed blood test
Go deeper with Bing News on:
- MD Anderson collaborates with Denali Therapeutics to advance novel therapies for neurodegenerative diseaseson February 20, 2020 at 3:02 pm
The University of Texas MD Anderson Cancer Center today announced a strategic research collaboration with Denali Therapeutics Inc. to develop novel therapies for Alzheimer's and other ...
- MD Anderson announces strategic collaboration with Denali Therapeutics to research and develop targeted therapies for neurodegenerative diseaseson February 20, 2020 at 12:53 pm
HOUSTON -- The University of Texas MD Anderson Cancer Center today announced a strategic research collaboration with Denali Therapeutics Inc. to develop novel therapies for Alzheimer's and other ...
- Annovis Issued Patent for Method of Treating Parkinson’s Disease and Other Lewy Body Diseaseson February 20, 2020 at 5:15 am
BERWYN, Pa., Feb. 20, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s, Parkinson’s and other neurodegenerative diseases, ...
- EnClear Therapies Nets $10M to Test Neuro Disease ‘Dialysis’ Deviceon February 19, 2020 at 5:39 pm
Many companies are working to develop new drugs that target harmful proteins associated with neurodegenerative diseases. EnClear Therapies has raised a $10 million Series A round of financing from a ...
- Alzheimer’s Disease Protein Clearance Mechanism Identifiedon February 19, 2020 at 5:00 am
The findings could point to new therapeutic targets for disorders such as Alzheimer’s disease and other neurodegenerative diseases, which are associated with the extracellular accumulation of abnormal ...